How insulin therapy
should feel like
should feel like
Our most valuable asset is the difference we make in people's lives.
Life sciences should be about leveraging infrastructures as well as intellect.
Innovation is found in products, processes, people, and thinking.
Healthcare should be accessible, safe and empowering.
Anxiety should be removed at all cost from healthcare.
Albania, Andorra, Armenia, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Croatia, Cyprus, Czech Republic (Czechia), Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Italy, Jordan, Latvia, Liechtenstein, Lithuania, Luxembourg, Macao, Malaysia, Malta, Monaco, Netherlands, New Zealand, Norway, Poland, Portugal, Qatar, Romania, San Marino, Saudi Arabia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Arab Emirates, United Kingdom.
The InsuJetTM community and medical professionals turn our scientific and medical discoveries into solutions for their life.
InsuJet™ has been in development for over two decades. We have been gathering clinical data and market feedback, for over a decade. At this stage we are confident that we are in a position to revolutionize the entire needle-free market.
2004 - Development of the technology starts in the UK.
2008 - Market approvel of the SQ-Pen. The first generation of the current family of needle-free inulin injection devices.
2009 - Global IP rights of technology acquired.
2010 - EU market approval.
2011 - InsuJet™ is covered by NHS.
2011 - Launch of the InsuJet™ V1.
2011 - 1st Clinical study
Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology.
Diabetes Care, August 2011
2012 - HK and China (CFDA) approval.
2013 - 2nd Clinical study into Needle-Free Jet Injection with Diabetes technology.
2014 - Australia (TGA) & New Zealand approval.
Launch of InsuJet™ V3.
New clinical studies validate and emphesize the effectiveness of InsuJet™ for patients of both type 1 and 2 diabetes.
InsuJet™ gets approval to sell in Malaysia.
InsuJet™ enters Middle East (KSA / JO)
Nugen MD acquires InsuJet™.
Canada HC approval.
Emergo appointed as UKRP.
InsuJet™ is signing new distributors in 10 new territories.
Used needles are a massive environmental concern. In the US alone, 7.8 bilion needles are disposed of on an annual basis, and most are for insulin use.
To fight this, we must push back on the use of single-use disposables. For every InsuJetTM user, we eliminate more than 1000 needles per year! That saves a lot of biohazardous waste and the added environmental cost of its collection.
In many countries where needles are not properly collected and disposed off. The elimination of single-use disposables helps to protect our environment.
Building innovative products requires working with world-class manufacturing partners and skilled employees. Our suppliers operate some of the most technologically advanced manufacturing facilities on the planet, designed to perform at the level of precision and quality necessary to build our products.
To maintain the highest level of conformity of our processes, we implement a Quality Management System that complies with ISO 13485:2016, which stipulates the requirments for medical device manufacturers and its suppliers to design, produce, store, distribute and dispose of medical devices. Our QMS is certified by our Notified Body, LNE/GMED, ID No. 0459. The InsuJetTM needle-free administration system is certified under MDD 93/42/EEC (until October 26, 2024), and currently under assessment of EU MDR 2017/745.
Our mission is to make the medical profession a safer place. Where needle-stick injuries are a thing of the past. Any needle-stick injury can cause emotional stress to healthcare workers as they are potentially exposed to dangerous patogents transmitting possible chronic and hazardous diseases. such as Hepetitus B, C and HIV.
Hospitals and clinics are required to provide safe medical devices to not only their patients, but to also their staff, to provide a safe and low risk work environment. Just like medical device manufacturers, they are the required to reduce risks to the lowest possible levels. This means that they need to provide safe alternatives to needles if available. NSI's with insulin delivery devices are the most common of all NSI's, and can be avoided with the InsuJetTM.
To ensure the device is safe to use, the device comes with an important safety feature, which is the counter-pressure release mechanism. This mechanism is designed to only release when it is pushed with the front of the device toward the target administation site. This prevents accidental firing, and makes the device more safe to use than other needle-free devices on the market without this feature.
We commit to continue improving the safety of needle-free technology by commiting to the best practices in Risk Management, Clinical Evaluation, Usability Engineering and Post Market Surveillance. We conduct Post Market Clinical Follow up studies to actively collect feedback on the clinical peformance of the devices in the market, so can continue to improve, making needle-free technology better and safer with every generation of devices.
The InsuJetTM team and its suppliers are held to the highest standards of labor and human rights, health and safety, environmental stewardship, and ethics.
We take care of our employees, who are critical to the success of the company, as they possess the know-how and understanding on how to design, manufacture and sell innovative medical devices according to the state of the art.
We take care of our distributors, who are our most important link to the end-users of the device. We rely on them to, not only make the device available, but to provide you with the best instructions possible to start using the InsuJetTM. We also rely on them to support you, and provide us with important feedback of how our devices are performing in ther market.
But maybe most importantly we try to take care of our end-customers, our early adopters and brand advocates, who are critical to not just our success, but to the success of needle-free technology in general.
Our worldwide corporate operations consider a sustainable approach. Not just reducing the use of (biohazardous) needles and its collection.
Sustainability is at the forefront of what we do. This is reflected by the clear choice for durability as opposed to the common medical industry trend of using single-use disposables.
The InsuJet needle-free injector is spring powered, which is more sustainable than gas powered alternatives that are on the market. The spring can be re-set by simply winding your device, so the energy needed for every injection is provided by you! This does not require any external tools, such as reset boxes, as is seen in competitor devices.
Our devices are build to last, and we warrant that our devices are free of defects under normal conditions of use or storage and within the indicated lifetime and expiration date.
01.兼容的胰岛素类型：人和动物；速效胰岛素（推注）；速效胰岛素类似物；常规人胰岛素；基础胰岛素；中效，通常：NPH/ 异丙烷；长效，常用：甘精、地特米尔、德谷；预混料（例如 30/70）。
02.在一项用户调查中，78% 的受访者回答他们会向其他人推荐 InsuJet™。
03. 在一项用户调查中，40% 的受访者表示他们注意到使用较少的胰岛素。
04.无针喷射速效胰岛素可改善糖尿病患者的早期餐后血糖控制。糖尿病护理，2013 年 10 月。
05.体重指数和无针喷射注射对速效胰岛素类似物的疗效，事后分析。糖尿病、肥胖和代谢，2012 年 7 月。
06.使用无针喷射技术改进速效胰岛素的药代动力学和药效学特征。糖尿病护理，2011 年 8 月
07.一项初步研究，以检查 InsuJet™ 与皮下注射相比对 1 型糖尿病患者的胰岛素耐受性和设备偏好。糖尿病技术与治疗学，2014 年。
09.用皮下注射针头每天注射 4 次计算。一年中的每一天，每天注射 4 针，每年可节省 1,460 根针头。
*。 InsuJet™ 针对 U-100 胰岛素进行了校准
**。 针规 26-27 常用于皮下注射，直径约为 0.40 - 0.45mm。 InsuJet™ 喷嘴的孔口直径约为 0.15 毫米，远小于用于皮下注射胰岛素的传统针规。
***。 https://pubmed.ncbi.nlm.nih.gov PMID:18820853